Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan; Division of Gastroenterology, Taipei Veterans General Hospital, Taipei, Taiwan; National Yang-Ming University Hospital, Yilan, Taiwan.
Hepatology. 2015 May;61(5):1672-84. doi: 10.1002/hep.27679. Epub 2015 Mar 23.
Portal hypertension (PH), a pathophysiological derangement of liver cirrhosis, is characterized by hyperdynamic circulation, angiogenesis, and portosystemic collaterals. These may lead to lethal complications, such as variceal bleeding. Caffeine has been noted for its effects on liver inflammation, fibrogenesis, and vasoreactiveness. However, the relevant influences of caffeine in cirrhosis and PH have not been addressed. Spraque-Dawley rats with common bile duct ligation-induced cirrhosis or sham operation received prophylactic or therapeutic caffeine treatment (50 mg/kg/day, the first or 15th day since operation, respectively) for 28 days. Compared to vehicle (distilled water), caffeine decreased cardiac index, increased systemic vascular resistance, reduced portal pressure (PP), superior mesenteric artery flow, mesenteric vascular density, portosystemic shunting (PSS), intrahepatic angiogenesis, and fibrosis without affecting liver and renal biochemistry. The beneficial effects were reversed by selective adenosine A1 agonist N6-cyclopentyladenosine (CPA) or A2A agonist GCS21680. Both prophylactic and therapeutic caffeine treatment decreased portal resistance and PP in thioacetamide (200mg/kg, thrice-weekly for 8 weeks)-induced cirrhotic rats. Caffeine down-regulated endothelial nitric oxide synthase, vascular endothelial growth factor (VEGF), phospho-VEGFR2, and phospho-Akt mesenteric protein expression. Caffeine adversely affected viability of hepatic stellate and sinusoidal endothelial cells, which was reversed by CPA and GCS21680. On the other hand, caffeine did not modify vascular response to vasoconstrictors in splanchnic, hepatic, and collateral vascular beds.
Caffeine decreased PP, ameliorated hyperdynamic circulation, PSS, mesenteric angiogenesis, hepatic angiogenesis, and fibrosis in cirrhotic rats. Caffeine may be a feasible candidate to ameliorate PH-related complications in cirrhosis.
探讨咖啡因对肝硬化门静脉高压(PH)的影响及潜在机制。
采用胆总管结扎(BDL)诱导的肝硬化大鼠模型和硫代乙酰胺(TAA)诱导的肝硬化大鼠模型,给予预防性或治疗性咖啡因(50mg/kg/天)处理 28 天,观察咖啡因对大鼠血流动力学、门脉压力(PP)、肠系膜血管密度、门体分流(PSS)、血管生成和纤维化的影响。
与对照组相比,咖啡因降低了大鼠的心脏指数,增加了系统血管阻力,降低了 PP、肠系膜上动脉血流、肠系膜血管密度、PSS、肝内血管生成和纤维化,而不影响肝肾功能。这些作用被选择性腺苷 A1 受体激动剂 N6-环戊基腺苷(CPA)或 A2A 受体激动剂 GCS21680 逆转。预防性和治疗性咖啡因处理均可降低 TAA 诱导的肝硬化大鼠的门静脉阻力和 PP。咖啡因下调内皮型一氧化氮合酶、血管内皮生长因子(VEGF)、磷酸化 VEGFR2 和磷酸化 Akt 的肠系膜蛋白表达。此外,咖啡因还降低了肝星状细胞和窦内皮细胞的活力,而 CPA 和 GCS21680 可逆转这一作用。
咖啡因可降低肝硬化大鼠的 PP,改善高动力循环、PSS、肠系膜血管生成、肝内血管生成和纤维化,提示咖啡因可能是改善肝硬化相关 PH 并发症的一种可行候选药物。